NMT Medical CardioSeal
This article was originally published in The Gray Sheet
Executive SummarySeptal occluder cardiac implant receives second FDA humanitarian use designation approval, expanding use to include closure of ventricular septal defects that cannot be closed using standard surgical approaches, the firm announces Sept. 28. On Sept. 9, NMT announced FDA approval for humanitarian use (under 4,000 patients) of the device to close fenestrated Fontan procedures (1"The Gray Sheet" Sept. 13, In Brief)
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.